TACE联合PMCT治疗中晚期肝癌的临床观察  

Clinical Study of TACE Combined with PMCT Therapy for Moderate or Advanced Stage of Liver Cancer

作　　者：周培华[1] 邓和军[1] 许国辉[2] 张彬[1] 

机构地区：[1]重庆市肿瘤研究所,重庆400030 [2]四川省肿瘤医院,成都610041

出　　处：《肿瘤预防与治疗》2009年第3期294-296,共3页Journal of Cancer Control And Treatment

摘　　要：目的:观察TACE联合PMCT治疗中晚期肝癌的治疗效果。方法:61例原发性中晚期肝癌患者随机分为两组,单纯TACE组30例,TACE联合PMCT组31例,所有患者先行肝动脉化疗栓塞术(TACE),TACE联合PMCT组于二周后再施行PMCT手术,治疗三周期后,对疗效进行评价。结果:TACE组的完全坏死率、1年生存率分别为43.3%、63.3%;而联合治疗组分别为83.9%、80.6%。两组间完全坏死率、1年生存率差异均有统计学意义(P<0.05)。结论:原发性中晚期肝癌患者采用TACE+PMCT疗效优于单纯TACE治疗。Objective： To observe the therapeutic effects of TACE combining PMCT therapy for moderate or advanced liver cancer. Methods： 61 cases of advanced liver carcinoma were divided into two groups, the TACE group included 30 cases and other 31 cases were in the TACE ＋ PMCT group. All cases were treated with TACE , and the TACE ＋ PMCT group were treated with PMCT after two weeks. The response rates of both groups were evaluated after 3 courses of treatment. Results： The necrosis rates of liver cancer and the 1 year survival rate were 43.3% and 63.3% respectively;while the TACE ＋ PMCT group were 83.9% and 80.6% respectively. There were significance difference between two groups for the necrosis rates and 1 year survival rate, P 〈 0.05. Conclusion ： The therapeutic effect of TACE combined with PMCT is much better than TACE alone for moderate or advanced liver cancer.

关 键 词：微波凝固 灌注 栓塞 肝癌 临床观察 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]